| [1] |
Oudejans I, Mosterd A, Zuithoff N, et al.Comorbidity drives mortality in newly diagnosed heart failure: a study among geriatric outpatients[J]. J Card Fail, 2012, 18(1): 47-52.
|
| [2] |
Dickstein K, Cohen-Solal A, Filippatos G, et al.ESC guidelines for the diagnosis and treatment of acute and chronic HF 2008: the task force for the diagnosis and treatment of acute and chronic HF 2008 of the European Society of Cardiology.Developed in collaboration with the HF Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [J]. Eur Heart J, 2008, 29(19):2388-2442.
|
| [3] |
Cleland JG, McDonagh T, Rigby AS, et al.The national HF audit for England and Wales 2008-2009[J]. Heart, 2011, 97(11): 876-886.
|
| [4] |
Hancock HC, Close H, Mason JM, et al.High prevalence of undetected heart failure in long-term care residents: findings from the Heart Failure in Care Homes (HFinCH) study[J]. Eur J Heart Fail, 2013, 15(2): 158-165.
|
| [5] |
Fonarow GC, Yancy CW, Heywood JT.Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry[J]. Arch Intern Med, 2005, 165(13): 1469-1477.
|
| [6] |
Alexander KP, Newby LK, Cannon CP, et al.Acute coronary care in the elderly, part I:non-ST-segment-elevation acute coronary syndromes a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology:in collaboration with the Society of Geriatric Cardiology[J].Circulation, 2007, 115(19):2549-2569.
|
| [7] |
王士雯．开展老年多病因心衰的临床和基础研究[J]．中华老年多器官疾病，2006，5(4): 244-245.
|
| [8] |
McMurray JJ, Adamopoulos S, Anker SD, et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2012, 33(14): 1787-1847.
|
| [9] |
Pfisterer M, Buser P, Rickli H, et al.BNP-guided vs symptom-guided HF therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with congestive HF (TIME-CHF) randomized trial[J]. JAMA, 2009, 301(4): 383-392.
|
| [10] |
Gaggin HK, Mohammed AA, Bhardwaj A, et al.HF outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic HF therapy (PROTECT) study[J].J Card Fail, 2012, 18(8):626-634.
|
| [11] |
Latini R, Masson S, Anand IS, et al. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure[J].Circulation, 2007, 116(11):1242-1249.
|
| [12] |
Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials[J].Circulation, 2012, 125(2): 280-288.
|
| [13] |
Adamson PB, Abraham WT, Aaron M, et al. Champion trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system[J].J Card Fail, 2011, 17(1):3-10.
|
| [14] |
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol, 2013, 62(16):e147-239.
|
| [15] |
中华医学会心血管病学分会，中华心血管病杂志编辑委员会．中国心力衰竭诊断和治疗指南2014[J]．中华心血管病杂志，2014，42(2): 98-122.
|
| [16] |
Masoudi FA, Rathore SS, Wang Y, et al.National patterns of use and effectiveness of angiotensin converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction[J]. Circulation, 2004, 110(6): 724-731.
|
| [17] |
Rochon PA, Sykora K, Bronskill SE, et al.Use of angiotensin-converting enzyme inhibitor therapy and dose-related outcomes in older adults with new heart failure in the community[J].J Gen Intern Med, 2004, 19(6):676-683.
|
| [18] |
Butler J, Forman DE, Abraham WT, et al.Relationship between heart failure treatment and development of worsening renal function among hospitalized patients[J].Am Heart J, 2004, 147(2):331-338.
|
| [19] |
Baruch L, Glazer RD, Aknay N, et al.Morbidity, mortality, physiologic and functinal parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial(VaL-HeFT) [J].Am Heart J, 2004, 148(6):951-957.
|
| [20] |
McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial[J].Lancet, 2003, 362(9386):767-771.
|
| [21] |
Dulin BR, Haas SJ, Abraham WT, et al. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of more than 12,000 patients in large-scale clinical trials[J].Am J Cardiol, 2005, 95(7):896-898.
|
| [22] |
Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues[J].Drugs Aging, 2008, 25(2):131-144.
|
| [23] |
Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic HF and mild symptoms[J].N Engl J Med, 2011, 364:11-21.
|
| [24] |
Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes[J].Arch Intern Med, 2010, 170(7):631-637.
|
| [25] |
Verbrugge FH, Dupont M, De Vusser P, et al. Response to cardiac resynchronization therapy in elderly patients (≥70 years) and octogenarians[J].Eur J Heart Fail, 2013, 15(2):203-210.
|